This approach has been recently proposed in HCC, where a co-delivery system based on plasmid-condensed nanocomplexes with a liver-targeting polycation gene vector has been employed to mediate the delivery of the tumor-suppressor lncRNA maternally expressed gene 3 (MEG3), resulting in the inhibition of HCC cell proliferation, migration and invasion in vitro and the inhibition of tumor growth in vivo [70]. This evidence concerns the gene MEG3 and neoplasm.